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| INTRODUC TI ON
Autoimmune hepatitis (AIH) is a generally progressive chronic autoimmune hepatitis whose pathogenesis remains unclear. T cell-mediated events cascade triggered by environmental agents including virus and drugs leading liver necroinflammatory and fibrotic process was a well accepted assumption. 1 The presentation of AIH is heterogeneous and fluctuant. Symptoms of chronic liver disease, such as hepatomegaly, splenomegaly, or jaundice, are common, but sometimes nonspecific symptoms, such as malaise, fatigue, lethargy, itching, and arthralgia, may be the primary complaint. The AASLD and EASL guidelines recommend liver biopsy in AIH patients as a prerequisite for diagnosis, prognosis, and treatment decisions. 1, 2 Previous studies showed 7% of AIH patients were cirrhotic at the time of diagnosis, and the baseline fibrosis was a risk factor for progression of cirrhosis after treatment. 1 However, because of the invasiveness, risk of complications, and sample errors, the clinical application of liver biopsy is limited. Therefore, many investigators attempted to propose noninvasive diagnostic models based on routine laboratory tests to assess liver fibrosis. Chen B et al 3 used the RDW-to-platelet ratio (RPR) to predict severity of liver fibrosis in patients with chronic hepatitis B (CHB). Kekilli M et al 4 found that the peripheral blood neutrophil-to-lymphocyte ratio (NLR) could forecast advanced fibrosis with high sensitivity and specificity in CHB patients. Yen YH, et al 5 used aspartate aminotransferase-to-platelet ratio index (APRI) and fibrosis index based on the four factors to evaluate liver fibrosis in chronic hepatitis C patients. However, few studies about the evaluation of liver fibrosis by noninvasive indicators in AIH patients were reported at present.
In this retrospective study, we aimed to investigate the complete blood count, liver function indexes, and other previously published indexes to evaluate the diagnostic value of these indexes for predicting liver fibrosis in AIH patients. were in good condition for all routine tests, including liver function, blood routine, and abdominal ultrasonography. All subjects were precluded infection or inflammatory diseases within one month before blood collection. Venous blood of AIH patients was collected at the same day with liver biopsy during the first diagnosis as AIH. Venous blood of healthy controls was collected during physical examination.
| PATIENTS AND ME THODS

| Patients
| Methods
Demographic and clinical data were collected by reviewing medical records. Hematological complete blood count was tested by Sysmex 5000 hematology analyzer (Sysmex) using 2 mL EDTA-K 2 anticoagulated blood. The complete blood count parameters include white blood cell (WBC), neutrophil (NEU), lymphocyte (LY), monocyte (MON), red blood cell (RBC), hemoglobin (HGB), hematocrit (HCT), mean corpuscular volume (MCV), red blood cell distribution width-coefficient of variation (RDW-CV), red blood cell distribution width-standard deviation (RDW-SD), platelet (PLT), plateletcrit (PCT), and derived parameters NLR, lymphocyte-to-monocyte ratio (LMR), RDW-CV-to-PLT ratio (RDW-CV/PLT), RDW-SD-to-PLT ratio (RDW-SD/PLT), and platelet-to-lymphocyte ratio (PLR) according to the following formulas: NLR = Neutrophil(10 function parameters were tested by OLYMPUS AU5800 biochemistry analyzer (Beckman Coulter) using 3 mL coagulated peripheral blood after centrifugation at 2564 g for 10 minutes. The liver function parameters include total protein (TP), albumin (ALB), total bilirubin (TBIL), direct bilirubin (DBIL), aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyltransferase (GGT), alkaline phosphatase (ALP), and derived parameters AST-to-ALT ratio (AAR), ALB-to-GLB ratio (AGR), APRI, FIB-4, and GGT-to-PLT ratio (GPR) according to the following Abbreviations: AAR, AST-to-ALT ratio; AGR, ALB-to-GLB ratio; ALB, albumin; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyltransferase; GLB, globulin; HCT, hematocrit; HGB, hemoglobin; LMR, lymphocyte-to-monocyte ratio; MCV, mean corpuscular volume; MPV, mean platelet volume; NLR, neutrophil-to-lymphocyte ratio; PCT, plateletcrit; PDW, platelet distribution width; PLR, platelet-to-lymphocyte ratio; PLT, platelet; RBC, red blood cell; RDW-CV, red blood cell distribution width-coefficient of variation; RDW-CV/PLT, RDW-CV-to-PLT ratio; RDW-SD, red blood cell distribution width-standard deviation; RDW-SD/PLT, RDW-SD-to-PLT ratio; TBIL, total bilirubin; DBIL, direct bilirubin; TP, total protein; WBC, white blood cell. Abbreviations: AAR, AST-to-ALT ratio; AGR, ALB-to-GLB ratio; ALB, albumin; ALP, alkaline phosphatase; ALT, alanine aminotransferase; APRI, AST-to-PLT ratio index; AST, aspartate aminotransferase; DBIL, direct bilirubin; FIB-4, fibrosis index based on the four factors; GGT, gamma-glutamyltransferase; GLB, globulin; GPR, GGT-to-PLT ratio; HCT, hematocrit; HGB, hemoglobin; LMR, lymphocyte-to-monocyte ratio; MCV, mean corpuscular volume; MPV, mean platelet volume; NLR, neutrophil-to-lymphocyte ratio; PCT, plateletcrit; PDW, platelet distribution width; PLR, platelet-to-lymphocyte ratio; PLT, platelet; RBC, red blood cell; RDW-CV, red blood cell distribution width-coefficient of variation; RDW-CV/PLT, RDW-CV-to-PLT ratio; RDW-SD, red blood cell distribution width-standard deviation; RDW-SD/PLT, RDW-SD-to-PLT ratio; TBIL, total bilirubin; TP, total protein; WBC, white blood cell.
Liver biopsy guided by ultrasound under local anesthesia was performed in all patients using a 16-G disposable needle. A minimum of 1.0cm of liver specimen containing at least 10 portal tracts was required for diagnosis. The specimens were fixed in 10% formalin, embedded in paraffin, and stained with hematoxylin-eosin and Masson's trichrome. All biopsy specimens were analyzed by an experienced pathologist who was blinded to the clinical data. Liver fibrosis stages were evaluated according to the METAVIR scoring were classified as "no/minimal fibrosis" group, while patients with a grade of F3 or F4 were classified as "advanced fibrosis" group. indexes and liver fibrosis was accessed by binary logistic regression analysis. The "Enter" method was used in univariate logistic regression analysis, and the variables that were statistically significant were entered into multivariate logistic regression analysis. Receiver operating characteristic (ROC) curves were generated to assess the diagnostic performance of each index for liver fibrosis. The cutoff values with both high sensitivity and high specificity were preferred. A two-sided P < 0.05 was considered statistically significant.
| Statistical analysis
| RE SULTS
| Demographic data and laboratory parameters in AIH patients and healthy controls
The data of in vitro laboratory examination of AIH patients and healthy controls were analyzed and are shown in the advanced liver fibrosis group. There was no significant difference in gender between the two groups, but the age of patients in the advanced liver fibrosis group was significantly higher than that in the no/minimal liver fibrosis group. Among these in vitro laboratory parameters, RDW-CV, RDW-SD, RDW-CV/PLT, RDW-SD/ PLT, AAR, and FIB-4 in the advanced liver fibrosis group were significantly higher than in the no/minimal liver fibrosis group, while RBC, PLT, PCT, and ALB in the advanced liver fibrosis group were significantly lower than in the no/minimal liver fibrosis group, as shown in Table 2 .
| Analysis of risk factors associated with AIH fibrosis
Binary logistic regression analysis was performed to investigate risk factors associated with advanced liver fibrosis in AIH patients. As shown in Table 3 , among these in vitro laboratory parameters, hematological parameters HGB, HCT, RDW-SD, RDW-CV/PLT, RDW-SD/PLT, PLT, and PCT and liver function parameters ALB and FIB-4
were associated with liver fibrosis after univariate logistic regression analysis, but only RDW-SD/PLT was the independent risk factor to predict advanced fibrosis in AIH patients with an OR (95% CI) of 2.647 (1.383-5.170).
| Diagnostic performance of liver fibrosis risk factors
Receiver operating characteristic curves were adopted to evaluate the performance of indexes in identifying no/minimal fibrosis patients from advanced liver fibrosis patients, as shown in Figure 1 . Table 4 .
ROC analysis indicated that RDW-SD, RDW-CV/PLT, RDW-SD
| D ISCUSS I ON
AIH is a chronic progressive inflammatory liver disease with unspecific onset and heterogeneous clinical presentation. Liver fibrosis is one of the common complications during AIH progression, and even many patients were found with advanced fibrosis at the first time when diagnosed as AIH. Liver fibrosis is also crucial for the prognosis and treatment choice for AIH. Liver biopsy is the criterion standard for diagnosing liver fibrosis, but the clinical application of liver biopsy is limited because of the invasiveness, risk of complications, and sample errors. Therefore, it is necessary to involve other techniques Abbreviations: AAR, AST-to-ALT ratio; AGR, ALB-to-GLB ratio; ALB, albumin; ALP, alkaline phosphatase; ALT, alanine aminotransferase; APRI, AST-to-PLT ratio index; AST, aspartate aminotransferase; DBIL, direct bilirubin; FIB-4, fibrosis index based on the four factors; GGT, gammaglutamyltransferase; GLB, globulin; GPR, GGT-to-PLT ratio; HCT, hematocrit; HGB, hemoglobin; LMR, lymphocyte-to-monocyte ratio; MCV, mean corpuscular volume; MPV, mean platelet volume; NLR, neutrophil-to-lymphocyte ratio; PCT, plateletcrit; PDW, platelet distribution width; PLR, platelet-to-lymphocyte ratio; PLT, platelet; RBC, red blood cell; RDW-CV, red blood cell distribution width-coefficient of variation; RDW-CV/PLT, RDW-CV-to-PLT ratio; RDW-SD, red blood cell distribution width-standard deviation; RDW-SD/PLT, RDW-SD-to-PLT ratio; TBIL, total bilirubin; TP, total protein; WBC, white blood cell. to clinical pathophysiological status. 12 In this study, we found that WBC, neutrophils, lymphocytes, and LMR are significantly lower, while NLR and monocytes are remarkably higher in AIH patients compared with healthy controls, consistent with the previous study reported by Zeng T, et al 13 The reduction in peripheral neutrophils and lymphocytes in AIH patients may have resulted from the exhaustion or migration from blood to the liver, 14 while increased NLR indicated that AIH patients lost more lymphocytes than neutrophils in their peripheral blood. On the contrary, the amount of monocytes increased in AIH patients, which may be caused by continuous inflammation and mobilization of monocytes from the bone marrow to the peripheral blood. 15 The relationship between NLR and fibrosis was controversial in previous studies on whether NLR could be a new marker for predicting fibrosis in patients with nonalcoholic fatty liver disease. 16 In this study, neither NLR nor LMR showed any significant difference between the no/minimal liver fibrosis group and the advanced liver fibrosis group, indicating that NLR or LMR could not be a predictor of fibrosis in all kinds of liver diseases under different pathogenesis backgrounds.
TA B L E 3
We also found that MCV, RDW-CV, RDW-SD, RDW-CV/PLT, and RDW-SD/PLT are significantly higher, while RBC, HGB, and HCT are remarkably lower in AIH patients compared with healthy controls. Abbreviations: AAR, AST-to-ALT ratio; FIB-4, fibrosis index based on the four factors; PLR, platelet-to-lymphocyte ratio; RDW-CV/PLT, RDW-CV-to-PLT ratio; RDW-SD, red blood cell distribution width-standard deviation; RDW-SD/PLT, RDW-SD-to-PLT ratio.
other indexes, such as bilirubin and albumin; therefore, RDW-CV/ RDW-SD represents a relatively stable index. Consistent with many previous studies that reported that low PLT counts were associated with advanced liver fibrosis, [19] [20] [21] [22] we found decreased PLT and PCT in the advanced fibrosis group in AIH patients. The decreased PLT may be caused by hypersplenism and the reduced thrombopoietin production as a result of excessive damaged liver cells in advanced fibrosis patients.
23,24
As expected, higher serum TBIL, DBIL, ALT, AST, ALP, and GGT levels were found in AIH patients compared with healthy controls, consistent with other kinds of hepatitis. 13, 25 Protein synthesis is an important function of the liver. Protein synthesis ability declined along with hepatocytes damaging, 26 resulting in decreased serum levels of TP and ALB. While increased GLB was attributed to excessive autoantibodies produced in AIH patients. 27 Interestingly, although slightly elevated TBIL and DBIL and decreased ALT, ALP, and GGT were found in the advanced fibrosis group, which was well known as "biliary enzyme separation", 28 no significant differences were found between the no/minimal liver fibrosis group and the advanced fibrosis group in these parameters including TBIL, DBIL, ALT, AST, ALP, GGT, TP, ALB, and GLB, indicating that these liver enzymes could not predict liver fibrosis independently. We also evaluated the combined parameters such as AAR, APRI, and FIB-4, which were previously used to identify the presence of liver fibrosis and the severity of fibrosis in chronic hepatic C patients. [29] [30] [31] [32] [33] In our study, we found that AAR and FIB-4 were superior to APRI in distinguishing advanced liver fibrosis from no/minimal liver fibrosis in AIH patients. These results are consistent with the previous finding focused on AIH patients. 13 However, a study by Abdollahi M 34 concluded that FIB-4
and APRI were superior to AAR at distinguishing severe fibrosis from mild-to-moderate fibrosis in chronic hepatitis C patients. Moreover, a previous study focused on hepatitis B and C found that there was no significant relationship between the degree of liver fibrosis and the AAR score. 35 Therefore, we need different specific biomarkers to identify fibrosis stages in hepatitis with different pathogeny.
In light of the present study, we found that RDW-SD, RDW-CV/PLT, RDW-SD/PLT, AAR, and FIB-4 showed a valuable performance to identify advanced liver fibrosis after a ROC analysis, while only RDW-SD/PLT is an independent risk factor to predict advanced liver fibrosis through a multivariate logistic regression analysis. RDW-CV is calculated from the erythrocyte volume distribution histogram and represents the coefficient of variation of erythrocyte volume around mean corpuscular volume (MCV), while RDW-SD is calculated from the width of erythrocyte volume distribution curve at a level 20% above baseline and is expressed in femtoliters (fL). 36 A study reported by Robbins CS 37 indicated that RDW-CV had higher sensitivity and efficiency than RDW-SD when evaluating anisocytosis in microcytic MCV ranges. However, in normocytic and macrocytic MCV ranges, RDW-SD presented better performance than RDW-CV in evaluating anisocytosis. AIH patients had an elevated MCV (Table 1) , and our study showed that RDW-SD was superior to RDW-CV in identifying advanced liver fibrosis. This is concordant with the result of Wang J's study, which showed that RDW-SD rather than RDW-CV was one of the independent predictors of advanced fibrosis in patients with chronic hepatitis B.
38 Consistent with our study, Taefi A 39 showed that the RDW-to-platelet ratio can strongly predict the degree of fibrosis or cirrhosis in patients with chronic hepatitis such as chronic hepatitis B, chronic hepatitis C, alcoholic hepatitis, and primary biliary cirrhosis.
In conclusion, our study demonstrates for the first time that RDW-SD/PLT is an independent risk factor to predict advanced liver fibrosis in AIH patients. RDW-SD/PLT is a noninvasive indicator that could be easily obtained from hematological complete blood count, which is routinely tested for AIH patients in clinical laboratory.
Therefore, RDW-SD/PLT could serve as a routinely used reference indicator to monitor liver fibrosis in all AIH patients.
